DL-TBOA ammonium
Based on 1 publication(s) in Google Scholar
DL-TBOA ammonium is a potent non-transportable inhibitor of excitatory amino acid transporters with IC50s of 70 μM, 6 μM and 6 μM for excitatory amino acid transporter-1 (EAAT1), EAAT2 and EAAT3, respectively. DL-TBOA ammonium inhibits the uptake of [14C]glutamate in COS-1 cells expressing the human EAAT1 and EAAT2 with Ki valuesof 42 μM and 5.7 μM, respectively. DL-TBOA ammonium blocks EAAT4 and EAAT5 in a competitive manner with Ki values of 4.4 μM and 3.2 μM, respectively.
For research use only. We do not sell to patients.
- CAS No.: 2093503-71-8
- Formula: C11H16N2O5
- Molecular Weight:256.26
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) DL-TBOA ammonium
More
Biological Activity
|
EAAT1 |
EAAT2 |
EAAT3 |
DL-TBOA ammonium (70-350 μM; 48 hours) treatment concentration-dependently enhances SN38-induced loss of viability. DL-TBOA reversed Oxaliplatin-induced loss of viability[4].
DL-TBOA ammonium (350 μM; 24 hours) decreases p53 induction by SN38 and oxaliplatin[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT116 cells, LoVo cells
-
Concentration:70 μM, 350 μM
-
Incubation Time:48 hours
-
Result:Enhanced SN38-induced, and counteracted Oxaliplatin-induced, cell death.
-
Cell Line:HCT116 cells, LoVo cells
-
Concentration:350 μM
-
Incubation Time:24 hours
-
Result:Decreased p53 induction by SN38 and oxaliplatin.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats (180-250 g)[5]
-
Dosage:1 nmol, 3 nmol, 10 nmol
-
Administration:Intracerebroventricularly injection (i.c.v.)
-
Result:Dose dependently facilitated various somatic signs induced by Naloxone (0.1 mg/kg)-precipitated morphine withdrawal.
Chemical Information
-
CAS No. 2093503-71-8
-
Molecular Weight 256.26
-
Formula C11H16N2O5
-
SMILES
OC([C@@H](N)[C@@H](C(O)=O)OCC1=CC=CC=C1)=O.N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Chem Biol
Electrochemical sensor toolkit for simultaneous glutamate detection at edge of cleft and peri-soma. [Abstract]2025 Jun 19;32(6):885-898.e11. PMID: 40466640
Purity & Documentation
References
[1]. Shimamoto K, et al. DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998 Feb;53(2):195-201. [Content Brief]
[2]. Jabaudon D, et al. Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8733-8. [Content Brief]
[3]. Shigeri Y, et al. Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J Neurochem. 2001 Oct;79(2):297-302. [Content Brief]
[4]. Pedraz-Cuesta E, et al. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells. BMC Cancer. 2015 May 16;15:411. [Content Brief]
[5]. Yumiko Sekiya, et al. Facilitation of morphine withdrawal symptoms and morphine-induced conditioned place preference by a glutamate transporter inhibitor DL-threo-beta-benzyloxyaspartate in rats. Eur J Pharmacol. 2004 Feb 6;485(1-3):201-10. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DL-TBOA ammonium Related Classifications
HY-107522B Related Classifications
Powered by Bioz